Comparing the current results to its competitors, Finch Therapeutics Group Inc reported Revenue decrease in the 2 quarter 2024 year on year by 0 %, despite the revenue increase by the most of its competitors of 16.08 %, recorded in the same quarter.
Finch Therapeutics Group Inc 's Comment on Competition and Industry Peers
The company holds extensive patent coverage in the microbiome field, with patent families having priority dates earlier than many competitors. Its portfolio includes a patent family comprising 24 issued U.S. patents, one pending U.S. patent application, and granted foreign patents in multiple countries. The company has a licensing agreement with OpenBiome, granting a worldwide, non-exclusive license under certain intellectual property rights for specific uses related to Natural Products for treating recurrent Clostridioides difficile infection (CDI) in the United States. Under this agreement, OpenBiome has agreed not to license or transfer certain manufacturing technology rights to competitors and faces restrictions on the use, sale, and supply of products connected to competitors' clinical research. The license excludes any Natural Product involving lyophilized processed stool, such as CP101. The company made upfront and additional payments to OpenBiome as part of this agreement.
Publicly Traded Peers of Finch Therapeutics Group Inc
Iovance Biotherapeutics inc Share Performance
-5.57%
Over The Past 5 Days
Iovance Biotherapeutics inc
Profile
Iovance Biotherapeutics Inc operates on a business model centered around developing and commercializing novel cancer immunotherapy treatments. The company focuses on utilizing its proprietary Tumor Infiltrating Lymphocyte (TIL) therapy, which involves collecting and expanding a patient's own immune cells to target and kill cancer cells. Iovance primarily seeks to advance its TIL therapy candidates through clinical trials and collaborations while aiming to provide effective and personalized treatment options for cancer patients.
Seres Therapeutics Inc focuses on the development and commercialization of microbiome-based therapeutics to treat serious diseases by harnessing the potential of the human microbiome.
Molecular Partners Ag is a biotechnology company that operates on an innovative business model focused on the development of therapeutic drugs. The company utilizes its proprietary DARPin technology platform to create a pipeline of potential treatments for various diseases. Molecular Partners Ag primarily collaborates with strategic partners, including pharmaceutical companies, to advance its drug candidates through preclinical and clinical development stages.
Moderna Inc's business model revolves around the development and commercialization of mRNA-based therapeutics and vaccines. They focus on using messenger RNA (mRNA) technology to create drugs that can help prevent and treat various diseases.
Sources:
Finch Therapeutics Group Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Finch Therapeutics Group Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
